- Report
- November 2025
- 192 Pages
Global
From €3151EUR$3,545USD£2,750GBP
€3501EUR$3,939USD£3,055GBP
- Report
- September 2025
- 250 Pages
Global
From €3991EUR$4,490USD£3,482GBP
- Report
- April 2025
- 175 Pages
Global
From €3991EUR$4,490USD£3,482GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €889EUR$1,000USD£776GBP
€1111EUR$1,250USD£969GBP
- Report
- December 2025
- 191 Pages
Global
From €5199EUR$5,850USD£4,537GBP
- Report
- October 2025
- 160 Pages
Global
From €3511EUR$3,950USD£3,064GBP
- Report
- October 2025
- 160 Pages
Global
From €3511EUR$3,950USD£3,064GBP
- Report
- September 2025
- 112 Pages
Global
From €3500EUR$4,219USD£3,161GBP
- Report
- August 2025
- 180 Pages
Global
From €3151EUR$3,545USD£2,750GBP
€3501EUR$3,939USD£3,055GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €889EUR$1,000USD£776GBP
€1111EUR$1,250USD£969GBP
- Report
- December 2025
- 291 Pages
Global
From €5199EUR$5,850USD£4,537GBP
- Report
- July 2025
- 155 Pages
Global
From €4133EUR$4,650USD£3,607GBP
- Report
- May 2025
- 150 Pages
Global
From €5288EUR$5,950USD£4,615GBP
- Report
- November 2025
- 186 Pages
Global
From €3151EUR$3,545USD£2,750GBP
€3501EUR$3,939USD£3,055GBP
- Report
- November 2025
- 197 Pages
Global
From €3151EUR$3,545USD£2,750GBP
€3501EUR$3,939USD£3,055GBP
- Report
- November 2025
- 187 Pages
Global
From €3151EUR$3,545USD£2,750GBP
€3501EUR$3,939USD£3,055GBP
- Report
- November 2025
- 197 Pages
Global
From €3151EUR$3,545USD£2,750GBP
€3501EUR$3,939USD£3,055GBP
- Report
- November 2025
- 199 Pages
Global
From €3151EUR$3,545USD£2,750GBP
€3501EUR$3,939USD£3,055GBP
- Report
- November 2025
- 185 Pages
Global
From €3151EUR$3,545USD£2,750GBP
€3501EUR$3,939USD£3,055GBP
- Report
- November 2025
- 186 Pages
Global
From €3151EUR$3,545USD£2,750GBP
€3501EUR$3,939USD£3,055GBP

The Anti Tumour Necrosis Factor (anti-TNF) market is a subset of the Immune Disorders Drugs market. Anti-TNF drugs are used to treat a variety of immune-mediated diseases, such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. These drugs work by blocking the action of TNF, a protein that is involved in inflammation and tissue destruction. Anti-TNF drugs are generally administered as injections or infusions, and are often used in combination with other medications.
The anti-TNF market is highly competitive, with a number of companies offering products. These include AbbVie, Amgen, Janssen, Merck, Pfizer, and UCB. Each company has its own portfolio of anti-TNF drugs, and they are continually developing new products to meet the needs of patients. Show Less Read more